2 years ago

Glox Therapeutics Secures £4.3M Seed Funding for Precision Antibiotic Therapies

  • Glox Therapeutics, a Glasgow-based developer of precision antibiotic therapies, has raised £4.3M in seed funding led by Boehringer Ingelheim Venture Fund and Scottish Enterprise

  • The company intends to use the funds to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria, establish laboratories in Oxford and Glasgow, and expand its team

  • Glox Therapeutics is developing precision antibiotics utilizing engineered protein bacteriocins, which exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens.

      • ProblemHealthcare

      "Antibiotic resistance is a growing global health threat, with Gram-negative bacteria posing a significant challenge. Traditional antibiotics are losing their effectiveness, leading to limited treatment options and increased mortality rates."

      Solution

      "Glox Therapeutics is developing a new class of precision antibiotics based on engineered protein bacteriocins. These bacteriocins exhibit remarkable potency and specificity, enabling them to target specific Gram-negative pathogens, like Pseudomonas aeruginosa and Klebsiella pneumoniae, that have developed antibiotic resistance."

      Covered on